Compare Sanofi SA (SNY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Travere Therapeutics Inc. Common Stock — how do they compare? Sanofi SA trades at $39.99 (market cap $94.58B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Sanofi SA is far larger — about 19.4× Travere Therapeutics Inc. Common Stock's market cap, and Sanofi SA pays a 6.18% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SNY | TVTX | |
|---|---|---|
Market Cap | $94.58B | $4.88B |
Volume | 3,988,460 | 1,668,577 |
Sector | Health | Health |
52-Week High | $52.34 | $67.52 |
52-Week Low | $39.12 | $26.79 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $113.80B | $5.01B |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $39.77, up 0.08% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and announced a significant expansion of its immunology alliance with Regeneron, valued up to $8 billion. Revenue for 2025 was $46.72 billion, with net income of $7.81 billion, reflecting a profit margin of 16.72%.
The outlook is mixed; recent collaborations and earnings beats provide growth catalysts, but a projected decline in 2026 net income to $4.0 billion and bearish technical indicators suggest near-term headwinds. Risks include execution of new partnerships and competitive pressures in the pharmaceutical sector.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
